



Domain Therapeutics, a new name in GPCR drug discovery

Strasbourg, France, December 1st, 2008 - Domain Therapeutics, a drug discovery company focused on the identification of allosteric modulators of G Protein-Coupled Receptors (GPCRs), announces today that it has adopted a new company name, previously Faust Pharmaceuticals, to better reflect its new business model and activities. Until recently the company has exploited its unique GPCR technology to build its own pipeline and has now decided to give access to this proprietary platform to companies involved in GPCR drug discovery. In addition, Domain Therapeutics will conduct early development of its products on leading therapeutic indications.

The new name, Domain Therapeutics, also marks a transition from a strategy exclusively oriented towards a single therapeutic area (the diseases of the central nervous system) to a strategy directed towards a family of targets, GPCRs, whatever the indication.

"To our knowledge, there are no other specific technologies available for allosteric modulators," said Pascal Neuville, newly-named CEO of Domain Therapeutics. "Our platform represents therefore a key competitive advantage in an area of huge unmet need."

The technology has been validated on difficult targets including orphan GPCRs and Domain Therapeutics already has a pipeline of products, from hits to preclinical candidates, with excellent IP protection and acting on the most promising targets.

These favorable factors mean that Domain Therapeutics anticipates being able to raise funds and sign a number of collaborations on its technology platform, as well as build partnerships on its products.

About GPCRs

GPCRs are considered the best family of drug targets. They account for 40-50 per cent of the current drugs on the market, representing more than USD 30 billion in sales annually. The potential of this family remains tremendous as currently marketed GPCR drugs only target one third of the druggable GPCRs. To tackle this challenge, there is a need for new technologies able to address orphan and peptidic GPCRs that are often considered intractable. Another challenging area is the identification of a new class of GPCR ligands, allosteric modulators, which are considered safer drugs than the standard agonist/antagonist molecules. The combination of these unmet needs in the GPCR field with the key features of Domain Therapeutics' platform will allow the company to gain rapidly a significant portion of the huge market of GPCR drug discovery.

About Domain Therapeutics S.A.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform to identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform is also able to address difficult GPCRs such as orphans and peptidic receptors. The company's pipeline is composed of new chemical entities ranging from hits to preclinical candidates targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease and diabetes.

Contact Medias :

Andrew Lloyd & Associates

Andrew Lloyd – Marie-Laure Melchior

andrew@ala.com - marielaure@ala.com

Tel : +33 1 56 54 07 00
